{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:31:26Z","timestamp":1774686686967,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.4065\/82.5.543","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:29:19Z","timestamp":1232760559000},"page":"543-550","source":"Crossref","is-referenced-by-count":25,"title":["Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR Trial"],"prefix":"10.4065","volume":"82","author":[{"suffix":"Jr","given":"William","family":"Insull","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal K.","family":"Ghali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Hassman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph W.","family":"Ycas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elinor","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/82.5.543_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(96)00011-3","article-title":"Inadequate treatment with HMG-CoA reductase inhibitors by health care providers","volume":"100","author":"Marcelino","year":"1996","journal-title":"Am J Med"},{"key":"10.4065\/82.5.543_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9343(97)89459-4","article-title":"Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals","volume":"100","author":"Schectman","year":"1996","journal-title":"Am J Med"},{"key":"10.4065\/82.5.543_bib3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0002-9149(99)00117-4","article-title":"Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease [published correction appears in Am J Cardiol. 1999; 84:1143]","volume":"83","author":"Sueta","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.4065\/82.5.543_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.4065\/82.5.543_bib5","first-page":"147","article-title":"Cholesterol management in a population of managed care enrollees","volume":"10","author":"Harley","year":"2003","journal-title":"J Clin Outcomes Manage"},{"key":"10.4065\/82.5.543_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1524-4733.2005.00052.x","article-title":"Patterns and effectiveness of lipid-lowering therapies in a managed care environment","volume":"8","author":"Meyer","year":"2005","journal-title":"Value Health"},{"key":"10.4065\/82.5.543_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9149(03)00474-0","article-title":"Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events","volume":"92","author":"Foley","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.4065\/82.5.543_bib8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.4065\/82.5.543_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.4065\/82.5.543_bib10","first-page":"850","article-title":"Standardization of micromethods for plasma cholesterol, triglyceride, and HDL-cholesterol with the Lipid Research Clinics' methodology [abstract]","volume":"19","author":"Steiner","year":"1981","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.4065\/82.5.543_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763]","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.4065\/82.5.543_bib12","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update [published correction appears in Circulation. 2006;113: e847]","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.4065\/82.5.543_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.4065\/82.5.543_bib14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ejheart.2005.09.005","article-title":"A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics","volume":"7","author":"Kjekshus","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.4065\/82.5.543_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1468-6708-6-9","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients\u2014design and rationale of the AURORA study","volume":"6","author":"Fellstrom","year":"2005","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"10.4065\/82.5.543_bib16","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.4065\/82.5.543_bib17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.4065\/82.5.543_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jama.283.1.94","article-title":"Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease","volume":"283","author":"Lee","year":"2000","journal-title":"JAMA"},{"key":"10.4065\/82.5.543_bib19","first-page":"45","article-title":"Getting rewards for your results: pay-for-performance programs","volume":"11","author":"Endsley","year":"2004","journal-title":"Fam Pract Manag"},{"key":"10.4065\/82.5.543_bib20","first-page":"50","article-title":"Pay for performance gaining popularity: this evolving payment methodology holds significant implications for providers","volume":"19","author":"Ferman","year":"2004","journal-title":"Health Exec"},{"key":"10.4065\/82.5.543_bib22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1592\/phco.21.9.818.34563","article-title":"Assessment of hypercholesterolemia control in a managed care organization","volume":"21","author":"Straka","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.4065\/82.5.543_bib23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.4065\/82.5.543_bib24","series-title":"MarketScan [online database]","year":"2005"},{"key":"10.4065\/82.5.543_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000100908","article-title":"Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program","volume":"107","author":"Shepherd","year":"2007","journal-title":"Cardiology"},{"key":"10.4065\/82.5.543_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/pds.1281","article-title":"The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy","volume":"15","author":"McAfee","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.4065\/82.5.543_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/pds.1278","article-title":"Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study","volume":"15","author":"Goettsch","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611612767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T14:08:38Z","timestamp":1558102118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611612767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0025619611612767"],"URL":"https:\/\/doi.org\/10.4065\/82.5.543","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}